FDA Greenlights Imaging Agent to Detect Residual Cancer After Lumpectomy
Pegulicianine used with an approved imaging system achieved overall diagnostic accuracy of 84%
Stay updated with breaking news from Irene Wapnir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pegulicianine used with an approved imaging system achieved overall diagnostic accuracy of 84%
Discover the latest study of breast cancer surveillance in women with DCIS history, highlighting the importance of mammograms and self-exams.
NEWTON, Mass., March 25, 2024--Lumicell Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer detection during surgery, highlights presentations from clinical studies examining the use of investigational LUMISIGHT™ (pegulicianine) in combination with Lumicell™ Direct Visualization System (DVS) at the Society of Surgical Oncology Annual Meeting in Atlanta, Georgia, March 20-23, 2024.